

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (previously amended): A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, and wherein the vaccine does not include saponin.

Claim 2 (original): The vaccine of claim 1, further comprising a suitable adjuvant.

Claim 3 (currently amended): The vaccine of claim 1, wherein the amount of each inactivated biotype is at least 10^8 *M. bovis* ~~cell equivalents~~ cells.

Claim 4 (original): The vaccine of claim 1, wherein the amount of each attenuated biotype is at least 10^5 *M. bovis* cells.

C 1
Claim 5 (currently amended): A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, wherein at least one of the inactivated or attenuated *Mycoplasma bovis* biotypes is selected from the group consisting of biotype A, biotype B and Biotype C, and wherein the vaccine does not include saponin.

Claim 6 (currently amended): The vaccine of claim 5, wherein the amount of each selected inactivated *Mycoplasma bovis* biotype is at least 10^8 *M. bovis* ~~cell equivalents~~ cells.

Claim 7 (original): The vaccine of claim 5, wherein the amount of each selected attenuated *Mycoplasma bovis* biotype is at least 10^5 *M. bovis* cells.

Claim 8 (currently amended): ~~A~~ The vaccine of claim 1, wherein the vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least two inactivated or attenuated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient.

Claim 9 (original): The vaccine of claim 8, further comprising a suitable adjuvant.

Claim 10 (currently amended): The vaccine of claim 8, wherein the amount of each inactivated biotype is at least 10^8 *M. bovis* ~~cell equivalents~~ cells.

Claim 11 (original): The vaccine of claim 8, wherein the amount of each attenuated biotype is at least 10^5 *M. bovis* cells.

Claim 12 (original): The vaccine of claim 8, wherein the *Mycoplasma bovis* biotype is selected from the group consisting of biotype A, biotype B and biotype C.

Claims 13-20 (withdrawn)

Claim 21 (currently amended): A The vaccine of claim 1 comprising at least one inactivated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, wherein the vaccine is protective against *Mycoplasma bovis* mastitis in a bovine species following systemic administration.

Claim 22 (previously added): The vaccine of claim 21, comprising at least two inactivated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient, wherein the vaccine is protective against *Mycoplasma bovis* mastitis in a bovine species following systemic administration.

Claim 23 (canceled)

Claim 24 (previously added): The vaccine of claim 21, wherein the vaccine includes at least one inactivated *Mycoplasma bovis* biotype selected from the group consisting of biotype A, biotype B and biotype C.

Claim 25 (canceled)

Claim 26 (canceled)

Claim 27 (currently amended): ~~A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, and~~ The vaccine of claim 1, wherein the vaccine contains approximately 10^8 ~~cell equivalents~~ cells of each biotype in a volume of 2-5 milliliters.

Claim 28 (canceled)